References
Sandberg AA, Chen Z. Cancer cytogenetics and molecular genetics: clinical implications (review).
Int J Oncol.
1995;7:1241-1251.
Keating MJ, Smith TL, Kantarjian H, et al. Cytogenetic pattern in acute myelogenous leukemia: a major reproducible determinant of outcome.
Leukemia
. 1988;2(7):403-412.
Schiffer CA, Lee EJ, Tomiyasu T, et al. Prognostic impact of cytogenetic abnormalities in patients with de novo acute nonlymphocytic leukemia.
Blood
. 1989;73(1):263-270.
Data on file, Pharmacia & Upjohn Company, Kalamazoo, Mich.
LoCoco F, DeRossi G, Pasqualetti D, et al. CD7 positive acute myeloid leukaemia: a subtype associated with cell immaturity.
Br J Haematol
. 1989;73:480-485.
Miller WH Jr, Levine K, DeBlasio A, et al. Detection of minimal residual disease in acute promyelocytic leukemia by a reverse transcription polymerase chain reaction assay for the PML/RAR-alpha fusion mRNA.
Blood
. 1993;82(6):1689-1694.
Warrell RP Jr, Frankel SR, Miller WH Jr, et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-
trans
-retinoic acid).
N Eng J Med
. 1991;324(20):1385-1393.
Maruyama F, Stass SA, Estey EH, et al. Detection of
AML1/ETO
fusion transcript as a tool for diagnosing t(8;21) positive acute myelogenous leukemia.
Leukemia
. 1994;8(1):40-45.
Kusec R, Laczika K, Knöbl P, et al.
AML1/ETO
fusion mRNA can be detected in remission blood samples of all patients with t(8;21) acute myeloid leukemia after chemotherapy or autologous bone marrow transplantation.
Leukemia
. 1994;8(5):735-739.
Mufti GJ, Flandrin G, Schaefer H-E, et al.
An Atlas of Malignant Haematology
. London: Martin Dunitz Ltd; 1996; 7, 14, 16, 106, 172.
Shurtleff SA, Meyers S, Hiebert SW, et al. Heterogeneity in CBFß/MYH11 fusion messages encoded by the inv(16)(p13q22) and the t(16;16) (p13;q22) in acute myelogenous leukemia.
Blood
. 1995;85(12):3695-3703.
von Lindern M, Fornerod M, van Baal S, et al. The translocation (6;9), associated with a specific subtype of acute myeloid leukemia, results in the fusion of two genes,
dek
and
can
, and the expression of a chimeric, leukemia-specific dek-can mRNA.
Mol Cell Biol
. 1992(12)1687-1697.
Nucifora G, Begy CR, Erickson P, et al. The 3;21 translocation in myelodysplasia results in a fusion transcript between the
AML1
gene and the gene for EAP, a highly conserved protein associated with the Epstein-Barr virus small RNA EBER 1.
Proc Natl Acad Sci USA
. 1993;90:7784-7788.
Klinger HP, ed. Human gene mapping 11.
Cytogenet Cell Genet
(Basel). 1991;58(1-4):25,51.
Thirman MJ, Levitan DA, Kobayashi H, et al. Cloning of ELL, a gene that fuses to MLL in a t(11;19)(q23;p13.1) in acute myeloid leukemia.
Proc Natl Acad Sci USA
. 1994;91:12110-12114.
Greer JP, Kinney MC. Acute nonlymphocytic leukemia. In: Lee GR, Bithell TC, Foerster J, et al, eds.
Wintrobeís Clinical Hematology
. 9th ed. Philadelphia, Pa: Lea & Febiger;1993:1920-1945.
Berman E, Heller G, Santorsa J, et al. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia.
Blood
. 1991;77(8):1666-1674.
Vogler WR, Velez-Garcia E, Weiner RS, et al. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group study.
J Clin Oncol
. 1992;10(7):1103-1111.
Wiernik PH, Banks PLC, Case DC Jr, et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia.
Blood
. 1992;79(2):313-319.
Top
-
Leukemia Library Index
-
Detection Guide Index
